These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29112587)

  • 21. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
    Garnock-Jones KP
    Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
    Choi MR; Jiles C; Seibel NL
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aprepitant for antiemesis after laparoscopic gynaecological surgery: A randomised controlled trial.
    Ham SY; Shim YH; Kim EH; Son MJ; Park WS; Lee JS
    Eur J Anaesthesiol; 2016 Feb; 33(2):90-5. PubMed ID: 26694939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
    Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
    Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aprepitant for chemotherapy-induced nausea and vomiting.
    Flemm LA
    Clin J Oncol Nurs; 2004 Jun; 8(3):303-6. PubMed ID: 15208824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
    Pritchett W; Kinsley K
    Clin J Oncol Nurs; 2016 Oct; 20(5):555-6. PubMed ID: 27668376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer].
    Kameda K; Kiba T; Ogawa Y; Kimoto S; Kajiume S; Okada Y; Morii N; Takahashi H; Ichiba Y; Yamashiro H
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1255-7. PubMed ID: 25335710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
    Stiff PJ; Fox-Geiman MP; Kiley K; Rychlik K; Parthasarathy M; Fletcher-Gonzalez D; Porter N; Go A; Smith SE; Rodriguez TE
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):49-55.e1. PubMed ID: 22863840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
    Scher CS; Amar D; McDowall RH; Barst SM
    Can J Anaesth; 1992 Feb; 39(2):170-2. PubMed ID: 1544199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New drug works with antiemetics to control acute and delayed nausea and vomiting.
    Clin J Oncol Nurs; 2004 Jun; 8(3):239. PubMed ID: 15208817
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiemetic agents.
    Wilkes G
    Oncology (Williston Park); 2007 Jul; 21(8 Suppl):48. PubMed ID: 17844897
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
    Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.
    Borgeat A; Wilder-Smith O; Forni M; Suter PM
    Can J Anaesth; 1994 Nov; 41(11):1117-9. PubMed ID: 7828261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.